Back
Supreme Court Observes Inflated Medicine Prices by Hospitals Under Govt Schemes a 'Clear-Cut Fraud'
The on Tuesday made a powerful observation that is set to reverberate across the healthcare and pharmaceutical sectors. A bench comprising Justice Vikram Nath and Justice Sandeep Mehta stated that charging patients for medicines at prices far exceeding the manufacturer’s selling price amounts to a “,” particularly when hospitals later receive reimbursement from government health schemes funded by taxpayers. The remark came during the hearing of two petitions seeking tighter regulation of medicine pricing and highlighting the gross disparity between the cost at which drugs are supplied to retailers and the Maximum Retail Price (MRP) printed on them.
The Core Issue: MRP Disparity and Patient Exploitation
At the heart of the matter is the practice of corporate hospitals requiring patients to purchase medicines exclusively from hospital-owned pharmacies at full MRP, while the same drugs are available at significantly lower prices from independent chemists. Dr. Sanjay Kulshresthra, the petitioner in one of the cases, argued that traditional chemists often forgo part of their profit margin, but corporate hospitals leverage their captive market to charge the full MRP, coupled with a rider that the patient must buy from the hospital store. He further submitted that hospitals refuse to take responsibility for administering medicines procured elsewhere, effectively forcing patients into a costly, in-house purchase.
The bench took serious note of this coercive practice. Justice Mehta observed that under schemes like Ayushman Bharat (PMJAY), the cost of these inflated medicines is ultimately borne by the public exchequer. “Many patients are now getting treatment under the PMJAY, that, what do you say? Ayushman Bharat. So, ultimately, it's the taxpayer's money which goes into all this. Because the medicine, which is supposed to be sold for 200 rupees, is dispensed for 2,000 rupees, and the hospital gets the reimbursement, and the taxpayer pays it. This is a on the face of it,” Justice Mehta remarked.
Why the Huge MRP Margin?
Dr. Kulshresthra distinguished the roles of manufacturers and retailers in the pricing chain. He contended that manufacturers merely print the MRP, while the actual exploitation occurs at the retailer’s end. However, Justice Mehta pointed to the root cause: the permissibility of printing an MRP that is ten times the actual cost of the medicine. “Why this permissibility of printing the MRP 10 times the actual cost of the medicine? Why this? This is the leverage to the retailer to charge anything he wants,” the judge observed.
The Court also flagged a secondary issue of consumer confidence. If a chemist sells a medicine with an MRP of ₹5,000 for just ₹2,000, the patient may lose trust in the product’s authenticity. Dr. Kulshresthra countered that such a situation is unique to medicines and contrasted it with consumer electronics. “If you take a mobile phone, costing Rs. 50,000 on one shop, it may not be available in the same model, same company, same day, same city, it may not be available in Rs. 5,000. But in medicine, it is happening. The drug is costing Rs. 5,000, and it is available for Rs. 350 to my patient,” he submitted.
Legal and Regulatory Implications
The Supreme Court’s observation opens a critical debate on the adequacy of existing price control mechanisms under the , and the role of the . The bench questioned why a wide difference between the supply price and MRP should be allowed and whether a fixed criterion should be mandated to limit the disparity. This could potentially lead to a re-examination of the current ceiling on retail margins and the transparency of drug pricing.
From a legal perspective, the remarks signal that courts may treat systematic overpricing by hospitals under government health schemes as actionable fraud, possibly attracting criminal liability under the for . The observation also strengthens the argument for a more robust regulatory framework that mandates a direct link between the manufacturer’s price and the final price charged to the patient, especially when public funds are involved.
Impact on Healthcare and Legal Practice
For legal professionals, this case is a landmark in the evolving jurisprudence of healthcare fraud and consumer protection. The Supreme Court’s strong language (“”) provides a powerful tool for advocates representing patients or public interest litigants challenging similar practices. It also places hospitals on notice that their pricing strategies may come under increased judicial scrutiny, particularly when they benefit from government reimbursement schemes.
The petition also raises questions about the ethical obligations of hospitals under the and the regulations of the . If the Court ultimately directs a cap on MRP margins or mandates price transparency, it could fundamentally alter the business model of many corporate hospitals.
Next Steps
The matter has been adjourned to for hearing submissions from the respondents, including the Union of India and the EMRB. The Court is expected to consider whether a regulatory framework should be put in place to prevent the exploitation of patients and misuse of public funds. Legal observers will be watching closely, as the outcome could set a precedent for the entire healthcare industry.
In the meantime, the Supreme Court’s observation serves as a stark reminder that the nexus between inflated MRPs, captive hospital pharmacies, and government reimbursement schemes cannot continue unchecked. As Justice Mehta succinctly put it, when taxpayers end up footing the bill for prices ten times the actual cost, it is not just a pricing anomaly—it is a .
